The influence of carrier and drug morphology on drug delivery from dry powder formulations
- PMID: 12711183
- DOI: 10.1016/s0378-5173(03)00156-x
The influence of carrier and drug morphology on drug delivery from dry powder formulations
Abstract
Lactose was crystallised either from neutralised Carbopol 934 gel or from water-ethanol solution without stirring, with a view to obtaining lactose alpha-monohydrate of favourable shape and smooth surface, suitable for use as carriers in formulations for dry powder inhalers (DPIs). Crystallisation of salbutamol sulphate was carried out in the presence of water, lecithin and ethanol to form salbutamol crystals with defined shape and smooth surface. The crystals formed were needle-shaped, with a length of less than 6 microm and a width between 0.5 and 1 microm. DSC and TGA showed that lactose crystals produced from Carbopol gel or from water-ethanol solution existed as alpha-lactose monohydrate. The DSC thermograms of micronised and crystallised salbutamol sulphate showed two similar endothermic transitions at 200 and 290 degrees C, respectively. The first transition was initially thought to correspond to the melting of salbutamol sulphate. However, the shape of the particles as observed by optical microscopy was not altered after heating the sample to 250 degrees C, suggesting that no transition from solid to liquid state occurred at 200 degrees C. This was confirmed by observations made using hot stage microscopy. The two endothermic transitions are suggested to correspond to the decomposition of the salbutamol sulphate molecule. The elongation ratio of the commercial lactose crystals, lactose crystallised from Carbopol and from water-ethanol were 1.69+/-0.05, 2.01+/-0.13 and 6.25+/-0.17, respectively. As the elongation ratio increased the flow properties of the carrier were affected detrimentally and this consequently reduced the content uniformity of salbutamol sulphate and drug emission from the inhaler device. Whereas, increasing the elongation ratio of the carrier or drug improved the deposition profiles of salbutamol sulphate, suggesting that the more elongated particles would be more aerodynamic and favour deep lung penetration.
Similar articles
-
The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.Colloids Surf B Biointerfaces. 2012 Jan 1;89:29-39. doi: 10.1016/j.colsurfb.2011.08.019. Epub 2011 Sep 10. Colloids Surf B Biointerfaces. 2012. PMID: 21962946
-
Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler.Colloids Surf B Biointerfaces. 2010 Sep 1;79(2):345-56. doi: 10.1016/j.colsurfb.2010.04.016. Epub 2010 May 5. Colloids Surf B Biointerfaces. 2010. PMID: 20537870
-
Characterisation and deposition studies of recrystallised lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry powder inhalers.AAPS J. 2011 Mar;13(1):30-43. doi: 10.1208/s12248-010-9241-x. Epub 2010 Nov 6. AAPS J. 2011. PMID: 21057906 Free PMC article.
-
Dry powders for oral inhalation free of lactose carrier particles.Adv Drug Deliv Rev. 2014 Aug;75:32-52. doi: 10.1016/j.addr.2014.04.005. Epub 2014 Apr 13. Adv Drug Deliv Rev. 2014. PMID: 24735676 Review.
-
Lactose characteristics and the generation of the aerosol.Adv Drug Deliv Rev. 2012 Mar 15;64(3):233-56. doi: 10.1016/j.addr.2011.05.003. Epub 2011 May 13. Adv Drug Deliv Rev. 2012. PMID: 21616107 Review.
Cited by
-
Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study.AAPS PharmSciTech. 2009;10(3):993-1012. doi: 10.1208/s12249-009-9290-6. Epub 2009 Aug 1. AAPS PharmSciTech. 2009. PMID: 19649711 Free PMC article.
-
Particle engineering for pulmonary drug delivery.Pharm Res. 2007 Mar;24(3):411-37. doi: 10.1007/s11095-006-9174-3. Pharm Res. 2007. PMID: 17245651 Review.
-
Study of the RESS process for producing beclomethasone-17,21-dipropionate particles suitable for pulmonary delivery.AAPS PharmSciTech. 2008;9(1):39-46. doi: 10.1208/s12249-007-9004-x. Epub 2008 Jan 8. AAPS PharmSciTech. 2008. PMID: 18446459 Free PMC article.
-
Inhalable sustained-release formulation of glucagon: in vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity.Pharm Res. 2011 May;28(5):1157-66. doi: 10.1007/s11095-011-0379-8. Epub 2011 Feb 2. Pharm Res. 2011. PMID: 21287249
-
Aspherical, Nano-Structured Drug Delivery System with Tunable Release and Clearance for Pulmonary Applications.Pharmaceutics. 2024 Feb 5;16(2):232. doi: 10.3390/pharmaceutics16020232. Pharmaceutics. 2024. PMID: 38399290 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials